Compare
Tvardi Therapeutics, Inc. vs Equillium, Inc. vs Nuvectis Pharma, Inc. vs Dare Bioscience, Inc.
| Latest fiscal year | Tvardi Therapeutics, Inc. TVRD | Equillium, Inc. EQ | Nuvectis Pharma, Inc. NVCT | Dare Bioscience, Inc. DARE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $1.03M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/m |
| Gross margin | n/a | n/a | n/a | 71.3% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$18.21M | -$22.40M | -$26.44M | -$13.40M |
| EPS (Diluted) | -$3.26 | -$0.39 | -$1.32 | -$1.20 |
| Operating cash flow | -$23.50M | -$22.75M | -$16.01M | -$9.90M |
| Free cash flow | n/a | -$22.79M | n/a | -$10.29M |
| Cash & equivalents | $20.73M | $30.28M | $31.63M | $24.71M |
| Total assets | $32.07M | $31.89M | $31.71M | $32.47M |
| Total liabilities | $11.13M | $3.29M | $13.30M | $29.63M |
| Shareholders' equity | $20.95M | $28.60M | $18.41M | $2.84M |
| Return on year-end equity | -87.0% | -78.3% | -143.6% | -471.4% |
| Shares outstanding | 9.38M | 61.46M | 25.68M | 14.50M |
Revenue, most recent five fiscal years
| Fiscal year | Tvardi Therapeutics, Inc. | Equillium, Inc. | Nuvectis Pharma, Inc. | Dare Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $7.14M Ended 2024-12-31 | $41.09M Ended 2024-12-31 | n/a | $1.03M Ended 2025-12-31 |
| 1 year earlier | $20.97M Ended 2023-12-31 | $36.08M Ended 2023-12-31 | n/a | $9.8K Ended 2024-12-31 |
| 2 years earlier | $41.87M Ended 2022-12-31 | $15.76M Ended 2022-12-31 | n/a | $2.81M Ended 2023-12-31 |
| 3 years earlier | $23.03M Ended 2021-12-31 | n/a | n/a | $10.00M Ended 2022-12-31 |
| 4 years earlier | $135.08M Ended 2020-12-31 | n/a | n/a | $0 Ended 2021-12-31 |